INVO Fertility, Inc. has announced impressive financial results for the third quarter of 2026, showcasing a significant 28% growth in clinic revenue. This marks the seventh consecutive quarter where the company has reported positive adjusted EBITDA at the clinic level. The results, which were disclosed in a recent SEC filing, underscore the effectiveness of INVO's growth strategy, which includes a combination of organic expansion and strategic acquisitions.

On November 16, 2026, the company issued a press release detailing these financial results for the quarter ended September 30, 2026. The announcement is crucial as it reflects INVO's ongoing commitment to enhancing its operational performance and market presence within the surgical and medical instruments and apparatus sector.

Background

INVO Fertility, Inc. operates in the surgical and medical instruments and apparatus industry, classified under SIC code 3841. The company is publicly traded on the Nasdaq under the ticker symbol IVF. Based in Sarasota, Florida, INVO Fertility has undergone several name changes, most recently from NAYA Biosciences, Inc. in October 2024. The company is recognized for its innovative approaches in fertility treatments and related services.

What the Filing Says

The SEC filing indicates that INVO Fertility's press release highlighted record quarterly clinic revenues, driven by both organic growth and acquisitions. The filing states, "Seventh consecutive quarter of positive Clinic-Level Adjusted EBITDA," emphasizing the company's sustained financial health and operational efficiency.

Impact

This growth trajectory may significantly affect various stakeholders, including investors, employees, and competitors within the surgical and medical instruments sector. The positive results could bolster investor confidence and attract potential partnerships or acquisitions, further enhancing INVO's market position.

What's Next

The filing does not specify what happens next, but analysts and market observers will likely be keenly watching INVO Fertility's future filings for additional insights on its growth strategies and financial performance.